ELI LILLY & Co is 805.9x more valuable than Bicara Therapeutics Inc. by market capitalization ($1.070 T vs $1.33 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | BCAX | LLY |
|---|---|---|
| Market cap | $1.33 B | $1.070 T |
| US-listed rank | #2425 | #10 |
| Revenue (latest FY) | - | $65.18B |
| Net income (latest FY) | -$137.95M | $20.64B |
| Net margin | - | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 221 | 989 |
ELI LILLY & Co is 805.9x more valuable than Bicara Therapeutics Inc. by market capitalization ($1.070 T vs $1.33 B).
Full pages: Bicara Therapeutics Inc. and ELI LILLY & Co, or browse the full rankings.